Pet Supplement OEM & ODM: Novohope Oral Film Manufacturing

Novohope is a pet health supplement brand and contract manufacturer that pioneered pet oral dissolving membrane health products. Wuxi Novohope Biotechnology Co., Ltd., established in September 2025 in Wuxi, Jiangsu Province, China, offers brand agency, distribution, and OEM/ODM production services globally. Its portfolio spans seven functional supplement series — COAT+, EYES+, CALM+, BONE+, HEART+, PROBIO, and Fit+ — manufactured as oral fast-dissolving films (ODF) and orally disintegrating tablets (ODT).

The problem: conventional pet supplement formats and delivery barriers

For pet supplement brands, the delivery format is as important as the formula. Conventional forms — tablets, chewables, powders, and liquids — are frequently refused by pets, and forced feeding creates stress for animals and owners. The barrier is also physiological. Pets have short intestines (under 1.2 meters) and high stomach acid (pH 1–3), conditions that can degrade active ingredients before they reach the bloodstream.

Novohope's oral fast-dissolving film format is designed to address both barriers. When the film contacts pet saliva, it melts within 10 seconds, and the active ingredients are absorbed directly through the oral mucosa into the circulatory system. This route bypasses the gastrointestinal digestion that traditional oral supplements must endure, preserving more of the active ingredient before it reaches target tissues.

Industry background: a growing pet supplements market is shifting toward functional formats

Demand for pet health supplements continues to expand globally. The global pet supplements market is valued at approximately USD 2.8 billion in 2025 and is projected to reach USD 4.6 billion by 2033, according to Grand View Research. North America is the dominant regional market, accounting for 48.1% of global revenue share in 2025, while Asia-Pacific is projected as the fastest-growing region, driven by pet humanization and rising healthcare expenditure in China and India, according to Mordor Intelligence.

Within this market, oral dissolvable film (ODF) technology is emerging in the pet sector. Industry innovation in ODF technology focuses on disintegration times below 25 seconds and taste-masking palatability improvements of up to 47%, according to Market Reports World. Category data also shows strong consumer pull for functional formulas: top-selling dog tear stain supplements on major e-commerce platforms can reach monthly volumes of 100,000 units, according to ASINSIGHT.

Novohope's OEM/ODM solution for pet supplement brands

Novohope entered the market with a dedicated capability in oral fast-dissolving film and orally disintegrating tablet production for pet health supplements. The company reports an absorption rate of up to 95% with its oral melting film format, compared with approximately 35% for traditional products, and is the first global enterprise brand to release pet oral dissolving membrane health products.

Wuxi Novohope Biotechnology Co., Ltd. operates a 20,000 m² facility with a reported annual output capacity of 200,000,000 boxes. The R&D team comprises 12 engineers; the technical team originates from the Wahsheer Biotechnology Laboratory at the Chinese University of Hong Kong, and the core team is led by talent with experience in listed companies and the biomedicine field. About 95% of production is exported, with main markets in Europe, America, Britain, the Middle East, Japan, and South Korea.

OEM/ODM services and customization

• Production modes: brand agency, distribution, and OEM/ODM
• Customization: recipe/formula, brand identity, packaging design, and other bespoke requirements
• Monthly capacity: 200,000,000 units
• Lead time: 35–45 days
• Standard OEM MOQ: 3,000 units per SKU
• Quality control: 100% full inspection before delivery, plus third-party authoritative sampling testing
• Export markets: Europe, North America, Southeast Asia, Middle East, East Asia
• After-sales: remote support

Seven functional supplement series available for OEM and private label

Each series pairs an oral fast-dissolving matrix with function-specific nutrients. For example, EYES+ is positioned around eye care and tear stain care, while PROBIO targets digestive care with a probiotic-containing fast-dissolving matrix. COA test reports detail the ingredient composition of each product and are provided as part of the quality documentation.

Compliance: FDA registration, SDS, COA, and GS1

All Novohope products completed FDA food registration in July 2026 and obtained GS1 international product codes. The FDA Food Facility Registration (No. 18753066908) is valid through December 31, 2026. Individual products hold Safety Data Sheets (SDS) issued under the OSHA Hazard Communication Standard 29 CFR 1910.1200, and COA test reports cover products including COAT+ and HEART+. The EYES+ eye care and tear stain film was tested to US FDA 21 CFR 175.300. Testing documentation is issued by Shenzhen Deesev Testing International Corporation. In China, the company holds trademark application acceptance notices in Classes 7 and 31, dated February 12, 2026.

Global capability milestones

Novohope made its international debut in May 2026 at the International Pet Exhibition in Nuremberg, Germany, showcasing six products and receiving over 700 global customers, with more than 100 potential clients reached. In June 2026, the company opened a new R&D and marketing center in Shekou, Shenzhen. The company was selected for the “Feifeng Talent Program” — the Leading Technological Talent Project in 2025 — and shortlisted for the 2026 Wuxi Taihu Cup International Innovation Competition.

How the OEM/ODM process works: from brief to finished film

1. Submit a project brief. Provide target market, functional direction (for example tear stain care, joint mobility, or calming), format preference (ODF or ODT), and estimated volume.
2. Formula development. In ODM projects, the R&D team develops a custom recipe. In OEM projects, buyers select from the seven existing series.
3. Compliance review. Confirm target-market registration needs and collect relevant documentation, including FDA registration references, SDS, and COA reports.
4. Brand and packaging design. Customize brand identity and packaging design according to your go-to-market plan.
5. Sample production and approval. A sample order is accepted at an MOQ of 1 unit, delivered DDP, with pre-shipment full inspection and third-party testing documentation.
6. Bulk production. After sample approval, production runs at a monthly capacity of 200,000,000 units, with a standard lead time of 35–45 days.
7. Quality control and delivery. Each order receives 100% full inspection before shipment plus third-party authoritative sampling testing, and a COA quality report is provided.
8. Shipment. FOB/CIF terms are available at 1,000 boxes per SKU with 50/50 payment; DDP terms are available for sample and select orders.

Use cases: whom Novohope's OEM/ODM model serves

Private label for retail chains. A representative EM program combined private label production and ODM custom formula development across Germany, the UAE, Canada, Australia, France, and the US. The client ordered 200,000 units of oral films and tablets for chain supermarkets and retail stores under a three-year program. Reported results include a significant lift in pet health supplement category sales, favorable market feedback, and stable repeat orders. Green safety, ease of use, and pets not resisting the format were the highlighted advantages.

ODM formula development. Brands that need a proprietary formula can work with Novohope's 12-engineer R&D team to develop custom recipes around the oral fast-dissolving matrix.

Brand agency and distribution. Beyond manufacturing, Novohope offers brand agency and distribution arrangements for partners who want to carry the Novohope product line in their channels.

ODF/ODT vs conventional supplement formats: comparison

The comparison above is based on manufacturer-reported specifications. Industry ODF innovations target disintegration times below 25 seconds and palatability improvements up to 47% (Market Reports World, 2026). Buyers should evaluate format performance against their own claims dossier and target-market requirements.

FAQ

What certifications does Novohope hold for OEM pet supplement production?

All Novohope pet health supplement products completed FDA food registration in July 2026 (FDA Food Facility Registration No. 18753066908, valid through December 31, 2026) and obtained GS1 international product codes. Safety Data Sheets (SDS) are held for COAT+, EYES+, and BONE+ under OSHA Hazard Communication Standard 29 CFR 1910.1200. COA test reports cover products including COAT+ and HEART+. The EYES+ eye care and tear stain film was additionally tested to US FDA 21 CFR 175.300. Testing documents are issued by Shenzhen Deesev Testing International Corporation.

What OEM/ODM services does Novohope offer for pet health supplements?

Wuxi Novohope Biotechnology Co., Ltd. provides brand agency, distribution, and OEM/ODM production services globally. Customization includes recipe/formula development, brand identity, packaging design, and other customer-specific requirements. Clients can run OEM on existing series (COAT+, EYES+, CALM+, BONE+, HEART+, PROBIO, FIT+) or develop entirely new formulas through ODM.

Which formats can Novohope produce for pet supplements?

Novohope manufactures pet health supplements in two fast-dissolve formats: oral dissolvable films (ODF) and orally disintegrating tablets (ODT). Films melt within 10 seconds of saliva contact and are absorbed through the oral mucosa. Standard pack sizes range from 2.1 g to 2.5 g per 10-piece pack across the seven series.

What is the MOQ for OEM/ODM orders?

For standard OEM/ODM production, the MOQ is 3,000 units per SKU. For FOB/CIF shipments, the MOQ is 1,000 boxes per SKU with 50/50 payment terms. Sample orders are accepted at an MOQ of 1 unit under DDP terms with full payment before shipment.

Can I request samples before placing an order?

Yes. Novohope accepts sample orders with an MOQ of 1 unit, delivered DDP. Sample shipments include pre-shipment full inspection and third-party authoritative testing documentation, including a COA quality report. Sampling is the standard first step for brands evaluating format, palatability, and compliance evidence before bulk production.

What is the production lead time for OEM pet film orders?

The standard lead time is 35–45 days after sample and specification approval. Monthly production capacity is 200,000,000 units, supporting scaling from pilot to retail volume. Remote after-sales support is included.

How does Novohope control quality in private label production?

Every order undergoes 100% full inspection before delivery, plus third-party authoritative sampling testing, and a COA quality report accompanies shipments. All products completed FDA food registration in July 2026, and SDS documentation under OSHA HCS 29 CFR 1910.1200 supports US and international distribution. To start a sample request or obtain a quote, contact Frank at NovoHope.pet@outlook.com or WhatsApp +86 1626 232 2952.

Start your pet supplement OEM project with Novohope

Wuxi Novohope Biotechnology Co., Ltd. | Brand: Novohope
Website: novohope.pet | Blog: blog.novohope.pet
Email: NovoHope.pet@outlook.com | Tel: +86 1342809561 | WhatsApp: +86 1626 232 2952
Download the company brochure: Novohope Brand PDF

Conclusion

Pet supplement brands evaluating an OEM or ODM partner for oral dissolvable films need a supplier with dedicated ODF/ODT production, documented compliance, and private label experience. Wuxi Novohope Biotechnology Co., Ltd. combines a 20,000 m² facility, 200,000,000 units of monthly capacity, FDA registration, SDS/COA documentation, and a proven retail private label program across six export markets. The practical next step for buyers moving from evaluation to execution is a sample order, a COA review, and a formulation discussion.